Key result
Cessation of flecainide therapy in a patient with end-stage renal failure resulted in a fall in serum flecainide levels and resolution of adverse central nervous system effects.
Why the study?
Does cessation of flecainide therapy resolve severe central nervous system toxicity in a patient with end-stage renal failure?
Case Report (n=1)
Does cessation of flecainide therapy resolve severe central nervous system toxicity in a patient with end-stage renal failure?
Flecainide can cause severe central nervous system toxicity such as paranoid psychosis and myoclonus in patients with end-stage renal failure, which resolves upon drug cessation.
Answers are grounded in this paper and cite their sources.
Suggests reversible CNS toxicity with flecainide in ESRD; case report leaves open need for systematic study.
Flecainide is a sodium channel blocker used mainly in the treatment of supraventricular arrhythmias. Central nervous system side effects such as dizziness, visual disturbances, headache and nausea are commonly associated with flecainide, but severe central nervous system toxicity is rare. We report the first case of flecainide toxicity in a patient with end-stage renal failure. Cessation of flecainide therapy resulted in a fall in serum flecainide levels, with associated resolution of adverse central nervous system effects. We also review the pharmacokinetics of flecainide in patients with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Ting et al. (2008) conducted a case report in Flecainide toxicity in end-stage renal failure (n=1). Flecainide cessation was evaluated on Resolution of adverse central nervous system effects. Cessation of flecainide therapy in a patient with end-stage renal failure resulted in a fall in serum flecainide levels and resolution of adverse central nervous system effects.
Synapse has enriched 10 related papers. Consider them for comparative context: